ATE554102T1 - Therapeutische verwendungen von monoklonalen antikörpern gegen den angiotensin-ii typ-1 rezeptor - Google Patents
Therapeutische verwendungen von monoklonalen antikörpern gegen den angiotensin-ii typ-1 rezeptorInfo
- Publication number
- ATE554102T1 ATE554102T1 AT03792528T AT03792528T ATE554102T1 AT E554102 T1 ATE554102 T1 AT E554102T1 AT 03792528 T AT03792528 T AT 03792528T AT 03792528 T AT03792528 T AT 03792528T AT E554102 T1 ATE554102 T1 AT E554102T1
- Authority
- AT
- Austria
- Prior art keywords
- angiotensin
- type
- receptor
- monoclonal antibodies
- antibodies against
- Prior art date
Links
- 102000010913 Type 1 Angiotensin Receptor Human genes 0.000 title 1
- 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000005862 Angiotensin II Human genes 0.000 abstract 2
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 2
- 229950006323 angiotensin ii Drugs 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 210000002464 muscle smooth vascular Anatomy 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0219524.6A GB0219524D0 (en) | 2002-08-21 | 2002-08-21 | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
| PCT/GB2003/003758 WO2004018519A2 (en) | 2002-08-21 | 2003-08-21 | Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE554102T1 true ATE554102T1 (de) | 2012-05-15 |
Family
ID=9942753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03792528T ATE554102T1 (de) | 2002-08-21 | 2003-08-21 | Therapeutische verwendungen von monoklonalen antikörpern gegen den angiotensin-ii typ-1 rezeptor |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7951904B2 (de) |
| EP (2) | EP2228390B1 (de) |
| JP (2) | JP4652807B2 (de) |
| CN (2) | CN1681845B (de) |
| AT (1) | ATE554102T1 (de) |
| AU (1) | AU2003263294A1 (de) |
| CA (1) | CA2496422C (de) |
| DK (1) | DK1534750T3 (de) |
| ES (2) | ES2713057T3 (de) |
| GB (1) | GB0219524D0 (de) |
| WO (1) | WO2004018519A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219524D0 (en) | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
| FR2873699B1 (fr) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| WO2008060899A2 (en) * | 2006-11-09 | 2008-05-22 | Ore Pharmaceuticals Inc. | Breast cancer screening and treatment methods |
| GB0802931D0 (en) * | 2008-02-18 | 2008-03-26 | Queen Mary & Westfield College | Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions |
| MY163512A (en) * | 2009-09-03 | 2017-09-15 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| JP2011111422A (ja) * | 2009-11-27 | 2011-06-09 | Sekisui Chem Co Ltd | モノクローナル抗体 |
| CN103613660A (zh) * | 2013-11-25 | 2014-03-05 | 博奥赛斯（天津）生物科技有限公司 | 一种血管紧张素完全抗原的制备方法 |
| CN109467599B (zh) * | 2017-09-08 | 2021-06-04 | 武汉华纪元生物技术开发有限公司 | 短肽atr001以及由短肽制备具有偏向性调节at1r功能的单克隆抗体和应用 |
| US11191802B2 (en) | 2018-04-06 | 2021-12-07 | AMMA Therapeutics, Inc. | Composition for controlled release of therapeutic agents |
| CN115838425B (zh) * | 2022-08-31 | 2024-06-18 | 首都医科大学 | 一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5427922A (en) * | 1992-04-07 | 1995-06-27 | Takeda Chemical Industries, Ltd. | DNA encoding a new angiotensin II type 1 receptor subtype and its expression |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| GB9319877D0 (en) | 1993-09-27 | 1993-11-10 | Queen Mary | Novel hybridoma & monoclonal antibodies produced thereby |
| TW448185B (en) | 1993-11-05 | 2001-08-01 | Lilly Co Eli | Vaccine design and production |
| US6280994B1 (en) * | 1998-11-25 | 2001-08-28 | Zymogenetics, Inc. | Zace 1: a human metalloenzyme |
| WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| GB0219524D0 (en) | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
| US20060003483A1 (en) | 2003-07-07 | 2006-01-05 | Wolff Larry L | Optoelectronic packaging with embedded window |
-
2002
- 2002-08-21 GB GBGB0219524.6A patent/GB0219524D0/en not_active Ceased
-
2003
- 2003-08-21 EP EP10005016.0A patent/EP2228390B1/de not_active Expired - Lifetime
- 2003-08-21 WO PCT/GB2003/003758 patent/WO2004018519A2/en not_active Ceased
- 2003-08-21 AT AT03792528T patent/ATE554102T1/de active
- 2003-08-21 JP JP2004530398A patent/JP4652807B2/ja not_active Expired - Fee Related
- 2003-08-21 CA CA2496422A patent/CA2496422C/en not_active Expired - Fee Related
- 2003-08-21 CN CN038222051A patent/CN1681845B/zh not_active Expired - Fee Related
- 2003-08-21 DK DK03792528.6T patent/DK1534750T3/da active
- 2003-08-21 ES ES10005016T patent/ES2713057T3/es not_active Expired - Lifetime
- 2003-08-21 ES ES03792528T patent/ES2385976T3/es not_active Expired - Lifetime
- 2003-08-21 AU AU2003263294A patent/AU2003263294A1/en not_active Abandoned
- 2003-08-21 EP EP03792528A patent/EP1534750B1/de not_active Expired - Lifetime
- 2003-08-21 CN CN201010167267A patent/CN101837124A/zh active Pending
- 2003-08-21 US US10/525,277 patent/US7951904B2/en not_active Expired - Fee Related
-
2010
- 2010-01-04 JP JP2010000013A patent/JP5208975B2/ja not_active Expired - Fee Related
-
2011
- 2011-04-15 US US13/087,770 patent/US8383108B2/en not_active Expired - Fee Related
-
2013
- 2013-01-24 US US13/749,180 patent/US20130202604A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2496422C (en) | 2013-06-25 |
| CN1681845A (zh) | 2005-10-12 |
| WO2004018519A3 (en) | 2004-06-03 |
| EP1534750B1 (de) | 2012-04-18 |
| GB0219524D0 (en) | 2002-10-02 |
| ES2385976T3 (es) | 2012-08-06 |
| US8383108B2 (en) | 2013-02-26 |
| JP5208975B2 (ja) | 2013-06-12 |
| JP2006513982A (ja) | 2006-04-27 |
| US20060034839A1 (en) | 2006-02-16 |
| US20110256139A1 (en) | 2011-10-20 |
| DK1534750T3 (da) | 2012-07-23 |
| JP4652807B2 (ja) | 2011-03-16 |
| CN1681845B (zh) | 2011-08-17 |
| CA2496422A1 (en) | 2004-03-04 |
| US7951904B2 (en) | 2011-05-31 |
| CN101837124A (zh) | 2010-09-22 |
| WO2004018519A2 (en) | 2004-03-04 |
| JP2010106035A (ja) | 2010-05-13 |
| EP2228390A1 (de) | 2010-09-15 |
| EP1534750A2 (de) | 2005-06-01 |
| US20130202604A1 (en) | 2013-08-08 |
| EP2228390B1 (de) | 2018-12-19 |
| AU2003263294A1 (en) | 2004-03-11 |
| ES2713057T3 (es) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60334364D1 (de) | Behandlungsverfahren unter verwendung von anti-cd22-antikörpern | |
| NO20051048L (no) | Terapeutisk humant anti-IL-1R1 monoklonalt antistoff | |
| ZA200609407B (en) | Monoclonal antibodies to hepatocyte growth factor | |
| RU2009108147A (ru) | Иммуноглобулины | |
| GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
| ATE471946T1 (de) | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 | |
| DK1534335T3 (da) | FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf | |
| EE05212B1 (et) | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i | |
| PT1639011E (pt) | Anticorpos (dab) de domínio único peguilados | |
| EA200700391A1 (ru) | Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1 | |
| DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
| CY1109817T1 (el) | Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου | |
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| MXPA04011550A (es) | Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico. | |
| ATE554102T1 (de) | Therapeutische verwendungen von monoklonalen antikörpern gegen den angiotensin-ii typ-1 rezeptor | |
| ATE407147T1 (de) | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein | |
| ATE364396T1 (de) | Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern | |
| DE69535855D1 (de) | Calciumbindende rekombinante antikörper gegen protein c | |
| NO20064136L (no) | Anti-epcam-immunglobuliner | |
| ATE497392T1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
| EP2641611A3 (de) | Kombinationstherapie | |
| ATE490271T1 (de) | Rezeptor, dessen verwendung sowie mausantikörper | |
| NO20044105L (no) | VEGF peptider og anvendelse derav | |
| DK1551867T3 (da) | Anvendelse af poly-alfa-2,8-sialsyre-mimetiske peptider til modulering af NCAM-funktioner | |
| EP1483292A4 (de) | Mit bakteriellen collagen-bindenden proteinen kreuzreaktive monoklonale antikörper |